UNITED THERAPEUTICS Corp 8-K

What Happened

• United Therapeutics Corporation announced that, at its June 26, 2026 Annual Meeting, shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan (the 2026 Plan), which becomes effective June 26, 2026. The plan was recommended by the Board’s Compensation Committee and will be administered by that committee, composed of independent directors.
• The 2026 Plan permits grants of stock options, stock appreciation rights, restricted stock, restricted stock units, stock awards (including performance-based awards), and incentive bonuses.

Key Details

• Effective date: June 26, 2026.
• New shares added: 1,500,000 new shares plus the 2,413,730 shares that remained available for grant under the Prior Plan, for an initial total of 3,913,730 shares available under the 2026 Plan.
• Outstanding Prior Plan awards: 4,941,655 shares were subject to outstanding awards under the Prior Plan as of June 26, 2026; any such awards that are later canceled, forfeited, expire, or settled in cash will free up additional shares for the 2026 Plan.
• The company will not grant new awards under the Amended and Restated 2015 Stock Incentive Plan (Prior Plan); previously granted awards under the Prior Plan remain outstanding and unchanged.

Why It Matters

• For investors, approval of the 2026 Plan sets the framework for future equity compensation to directors, executives, employees, and other service providers — a common tool to attract, retain, and incentivize key personnel.
• The initial ~3.9 million-share increase establishes the immediate pool available for future grants; the additional 4.94 million shares tied to outstanding Prior Plan awards could further replenish availability if they are canceled or settled in cash.
• Because equity awards can dilute existing shareholders over time, investors should monitor future grant activity and the company’s disclosures about dilution and share usage in proxy statements and quarterly filings.